These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23289757)

  • 1. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.
    Dunne S; Shannon B; Dunne C; Cullen W
    BMC Pharmacol Toxicol; 2013 Jan; 14():1. PubMed ID: 23289757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions and attitudes of community pharmacists towards generic medicines.
    Dunne SS; Shannon B; Cullen W; Dunne CP
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1138-46. PubMed ID: 25351975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encouraging the use of generic medicines: implications for transition economies.
    King DR; Kanavos P
    Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Price differences between generic and innovator medicines in Brazil].
    Vieira FS; Zucchi P
    Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis.
    Kaplan WA; Wirtz VJ; Stephens P
    PLoS One; 2013; 8(9):e74399. PubMed ID: 24098644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases.
    Gray AL; Santa-Ana-Tellez Y; J Wirtz V
    Trop Med Int Health; 2016 Dec; 21(12):1504-1512. PubMed ID: 27671539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the market share of generic medicines influence the price level?: a European analysis.
    Dylst P; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beliefs, perceptions and behaviours of GPs towards generic medicines.
    Dunne SS; Shannon B; Cullen W; Dunne CP
    Fam Pract; 2014 Aug; 31(4):467-74. PubMed ID: 24895136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drugs: international trends and policy developments in Australia.
    Lofgren H
    Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perceptions of generic medicines: a mixed-methods study.
    Dunne S; Shannon B; Dunne C; Cullen W
    Patient; 2014; 7(2):177-85. PubMed ID: 24385381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pricing models for generic medicines to ensure long-term sustainable competition in Europe.
    Francois C; Gawlik G; Mestre-Ferrandiz J; Pana A; Perelman J; Yfantopoulos J; Simoens S
    Front Pharmacol; 2023; 14():1200641. PubMed ID: 37876734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.